Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

A Novel Primary Cell Line Model of Localized Prostate Cancer and Radioresistance—A Role for Nicotinamide N-Methyltransferase

Wright JA. et al, (2025), Cells, 14, 819 - 819

IRE1 activity regulates tumour and microenvironment cell lineage states while stratifying localised and metastatic prostate cancer.

Doultsinos D. et al, (2025)

Specificity of a polygenic score for aggressive prostate cancer.

Dornisch AM. et al, (2025)

Clonal phylogenies inferred from bulk, single cell, and spatial transcriptomic analysis of epithelial cancers.

Erickson A. et al, (2025), PLoS One, 20

Multiple Highly Methylated CpG Sites as Potential Epigenetic Markers for the Diagnosis of Prostate Cancer

Jean-Pierre R. et al, (2024)

IGFs regulate cancer cell immune evasion in prostate cancer

Nandakumar AM. et al, (2024)

Single cell and spatial transcriptomics highlight the interaction of club-like cells with immunosuppressive myeloid cells in prostate cancer.

Kiviaho A. et al, (2024), Nat Commun, 15

Author Correction: IRE1α-XBP1s pathway promotes prostate cancer by activating c-MYC signaling.

Sheng X. et al, (2024), Nat Commun, 15

Metabolic imaging across scales reveals distinct prostate cancer phenotypes

Sushentsev N. et al, (2024), Nature Communications, 15

Molecular analysis of archival diagnostic prostate cancer biopsies identifies genomic similarities in cases with progression post-radiotherapy, and those with de novo metastatic disease.

Charlton PV. et al, (2024), Prostate, 84, 977 - 990

Identifying proteomic risk factors for overall, aggressive, and early onset prostate cancer using Mendelian Randomisation and tumour spatial transcriptomics.

Desai TA. et al, (2024), EBioMedicine, 105

Adaptations of membrane trafficking in cancer and tumorigenesis.

Evergren E. et al, (2024), J Cell Sci, 137

Identifying proteomic risk factors for cancer using prospective and exome analyses of 1463 circulating proteins and risk of 19 cancers in the UK Biobank.

Papier K. et al, (2024), Nat Commun, 15

CDK9 inhibition activates innate immune response through viral mimicry.

Yalala S. et al, (2024), FASEB J, 38

Systemic interrogation of immune-oncology-related proteins in patients with locally advanced prostate cancer undergoing androgen deprivation and intensity-modulated radiotherapy.

Guldvik IJ. et al, (2024), World J Urol, 42

Intra-prostatic tumour evolution, steps in metastatic spread and histogenomic associations revealed by integration of multi-region whole-genome sequencing with histopathological features.

Rao S. et al, (2024), Genome Med, 16

Peroxisomal β-oxidation enzyme, DECR2, regulates lipid metabolism and promotes treatment resistance in advanced prostate cancer.

Mah CY. et al, (2024), Br J Cancer

Enhancing novel multimodality therapy for prostate cancer, combining radiotherapy, vascular-targeted photodynamic therapy, and anti-CD73 immunotherapy

Sjoberg HT. et al, (2024), EUROPEAN UROLOGY, 85, S2204 - S2204

Investigating the STING pathway in the prostate cancer tumour immune microenvironment and radiosensitivity

Chan CY. et al, (2024), EUROPEAN UROLOGY, 85, S2205 - S2205

Spatial transcriptomic clonal deconvolution identifies the lethal clone in Prostate Cancer (PCa) as defined by ability to metastasize to lymph nodes

Yin W. et al, (2024), EUROPEAN UROLOGY, 85, S1668 - S1669

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?